Journal of Peking University(Health Sciences) >
Clinical analysis of candidemia in immunocompetent patients
Received date: 2017-10-17
Online published: 2018-12-18
Objective: To investigate the etiological and clinical characteristics of immunocompetent patients with candidemia.Methods:The clinical and microbiological data of patients diagnosed as candidemia admitted in Peking University Third Hospital from January 2010 to June 2016 were retrospectively analyzed. Underlying diseases, Candida spp. colonization, clinical manifestations, microbiological data, treatment and the outcome were compared between the HIV-negative immunocompromised (IC) and nonimmunocompromised (NIC) patients.Results:A total of 62 cases diagnosed as candidemia were analyzed including 36 men and 26 women, with 16 to 100 years of age [(66.02±17.65) years]. There were 30 NIC and 32 HIV-negative IC patients respectively. In the NIC patients, there were 19 cases (19/30, 63.33%) with admission in intensive care unit (ICU), 21 (21/30, 70.00%) associated diabetes mellitus or uncontrolled hyperglycemia and 22(22/30,73.33%)receiving invasive mechanical ventilation,while in the HIV-negative IC patients, there were 8 (8/32, 25.00%),13 (13/32, 40.63%) and 7 (7/32, 21.88%) respectively (P<0.05). The NIC patients had higher acute physiology and chronic health evaluation (APACHEⅡ) scores and sequential organ failure assessment (SOFA) scores both at admission (19.98±5.81, 6.04±6.14) and candidemia onset (25.61±6.52, 12.75±8.42) than the HIV-negative IC patients (APACHEⅡ 15.09±5.82, 22.15±5.98) and SOFA 2.87±2.73, 7.66±5.64 respectively (P<0.05). In the NIC patients, twenty-one cases (21/30, 70.00%) died in hospital,while 14 cases (14/32, 43.75%) in HIV-negative IC.The crude mortality was significantly different between the two groups (P<0.05). By blood culture, Canidia albicans remained the the most prevalent isolates in all the patients. Clinical manifestation, Candida spp. colonization, etiology and drug susceptibility were also similar between NIC and HIV-negative IC patients (P>0.05).Conclusion:Candidemia in NIC patients tends to occur in those who are much more critically ill, more often admitted in ICU, and more frequently have diabetes mellitus or uncontrolled hyperglycemia and receive invasive mechanical ventilation than HIV-negative IC patients. NIC patients also have poorer prognosis than HIV- negative IC patients. Clinical manifestations, and microbiological characteristics are similar between HIV- negative IC and NIC patients.
Key words： Candida; Candidemia; Immunocompetent patients; Clinical manifestation; Prognosis
Yan-ling DING , Ning SHEN , Qing-tao ZHOU , Bei HE , Jia-jia ZHENG , Xin-mao ZHAO . Clinical analysis of candidemia in immunocompetent patients[J]. Journal of Peking University(Health Sciences), 2018 , 50(6) : 1063 -1069 . DOI: 10.19723/j.issn.1671-167X.2018.06.022
| [1] | 李光辉 . 念珠菌血症的诊断与抗真菌治疗[J]. 中国感染与化疗杂志, 2011,11(2):98-100. |
| [2] | Wisplinhoff H, Bischoff T, Tallent SM , et al. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study[J]. Clin Infect Dis, 2004,39(3):309-317. |
| [3] | Wang H, Xiao M, Chen SC , et al. In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 national China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study[J]. J Clin Microbiol, 2012,50(12):3952-3959. |
| [4] | Guery BP, Arendrup MC, Auzinger G , et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis[J]. Intensive Care Med, 2009,35(1):55-62. |
| [5] | Dimopoulos G, Karabinis A, Samonis G , et al. Candidemia in immunocompromised and immunocompetent critically ill patients: a prospective comparative study[J]. Eur J Clin Microbiol Infect Dis, 2007,26(6):377-384. |
| [6] | Giri S, Kindo AJ . A review of Candida species causing blood stream infection[J]. Indian J Med Microbiol, 2012,30(3):270-278. |
| [7] | Mikulska M, Bassetti M, Ratto S , et al. Invasive candidiasis in non-hematological patients[J]. Mediterr J Hematol Infect Dis, 2011,3(1):e2011007. |
| [8] | Safdar A, Bannister TW, Safdar Z . The predictors of outcome in immunocompetent patients with hematogenous candidiasis[J]. Int J Infect Dis, 2004,89(3):180-186. |
| [9] | Vigouroux S, Morin O, Moreau P , et al. Candidemia in patients with hematologic malignancies: analysis of 7 years’ experience in a single center[J]. Haematologica, 2006,91(5):717-718. |
| [10] | Charlson ME, Pompei P, Ales KL , et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation[J]. J Chronic Dis, 1987,40(5):373-383. |
| [11] | Marra AR, Bearman GM, Wenzel RP , et al. Comparison of severity of illness scoring systems for patients with nosocomial bloodstream infection due to Pseudomonas aeruginosa[J]. BMC Infect Dis, 2006,17(6):132. |
| [12] | León C, Ruiz-Santana S, Saavedra P , et al. EPCAN study group. A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization[J]. Crit Care Med, 2006,34(3):730-737. |
| [13] | Posteraro B, De Pascale G, Tumbarello M , et al. Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1→3)-β-D-glucan assay, Candida score, and colonization index[J]. Crit Care, 2011,15(5):R249. |
| [14] | Abe M, Kimura M, Araoka H , et al. Serum (1, 3)-beta-D-glucan is an inefficient marker of breakthrough candidemia[J]. Med Mycol, 2014,52(8):835-840. |
| [15] | Singer M, Deutschman CS, Seymour CW , et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3)[J]. JAMA, 2016,315(8):801-810 |
| [16] | 陈佰义 . 侵袭性念珠菌病早期经验治疗的临床思维[J]. 中华内科杂志, 2014,53(11):907-909 |
| [17] | Sims CR, Ostrosky-Zeichner L, Rex JH . Invasive candidiasis in immunocompromised hospitalized patients[J]. Arch Med Res, 2005,36(6):660-671 |
| [18] | Tragiannidis A, Tsoulas C, Kerl K , et al. Invasive candidiasis: update on current pharmacotherapy options and future perspectives[J]. Expert Opin Pharmacother, 2013,14(11):1515-1528. |
| [19] | Ahmad S, Khan Z . Invasive candidiasis: a review of nonculture-based laboratory diagnostic methods[J]. Indian J Med Microbiol, 2012,30(3):264-269. |
| [20] | 谢剑锋, 杨毅 . 重症医学科患者念珠菌血症早期诊断的困境与思路[J]. 中华内科杂志, 2015,54(5):456-457. |
| [21] | Del Bono V, Delfino E, Furfaro E , et al. Clinical performance of the (1, 3)-β-D-glucan assay in early diagnosis of nosocomial Candida bloodstream infections[J]. Clin Vaccine Immunol, 2011,18(12):2113-2117. |
| [22] | Jaijakul S, Vazquez JA, Swanson RN , et al.( 1, 3)-β-D-glucan as a prognostic marker of treatment response in invasive candidiasis[J]. Clin Infect Dis, 2012,55(4):521-526. |
| [23] | Lewis RE . Overview of the changing epidemiology of candidemia[J]. Curr Med Res Opin, 2009,25(7):1732-1740. |
| [24] | Pemán J, Cantón E, Mi?ana JJ , et al. Changes in the epidemiology of fungaemia and fluconazole susceptibility of blood isolates during the last 10 years in Spain: results from the FUNGEMYCA study[J]. Rev Iberoam Micol, 2011,28(2):91-99. |
| [25] | 吴吉芹, 朱利平, 区雪婷 , 等. 医院获得性念珠菌血症109例临床特点及预后分析[J]. 中华传染病杂志, 2011,29(4):206-210. |
| [26] | Playford EG, Nimmo GR, Tilse M , et al. Increasing incidence of candidaemia: long-term epidemiological trends, Queensland, Australia, 1999-2008[J]. J Hosp Infect, 2010,76(1):46-51. |
| [27] | Pfaller MA, Messer SA, Moet GJ , et al. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in intensive care unit (ICU) and non-ICU settings in the SENTRY Antimicrobial surveillance program (2008-2009)[J]. Int J Antimicrob Agents, 2011,38(1):65-69. |
| [28] | Marriott DJ, Playford EG, Chen S , et al. Australian candidaemia study. Determinants of mortality in non-neutropenic ICU patients with candidaemia[J]. Crit Care, 2009,13(4):R115. |
| [29] | Tumbarello M, Posteraro B, Trecarichi EM , et al. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia[J]. J Clin Microbiol, 2007,45(6):1843-1850. |
/
| 〈 |
|
〉 |